• CFTRinh-172: Mechanistic Insights and Advanced Utility in CF

  2026-05-15

  Explore the advanced scientific rationale and practical assay considerations for using CFTRinh-172, a potent CFTR inhibitor, in cystic fibrosis research. This comprehensive analysis integrates new mechanistic findings and guidance for experimental design.

• Par6 Drives Processive Lgl Phosphorylation in Epithelial Pol

  2026-05-15

  This study elucidates how the polarity protein Par6 enables efficient, processive phosphorylation of Lgl by forming a dynamic ternary complex with aPKC. The findings reveal a mechanistic basis for epithelial polarity regulation and offer structural insights that can inform future protein phosphorylation analysis.

• Bone-Penetrating Baicalein–Copper Nanoassemblies Enable Cupr

  2026-05-14

  This study introduces a baicalein–copper nanoassembly with a boron-dipyrromethene photosensitizer, engineered for synergistic chemodynamic and photodynamic cancer therapy. The nanoplatform achieves targeted, bone-penetrating delivery, robust ROS generation, and induction of cuproptosis, addressing key limitations of traditional therapies and advancing treatment strategies for bone-metastatic tumors.

• Miltefosine Activates ERK to Restore Neutrophils in Leukopen

  2026-05-14

  This study demonstrates that miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) promotes neutrophil differentiation by activating the Ras/MEK/ERK pathway, effectively restoring white blood cell counts and bone marrow function in irradiation-induced leukopenia models. These findings clarify miltefosine's mechanism beyond PI3K/Akt inhibition, offering new experimental strategies for hematological recovery.

• Deferoxamine Mesylate: Iron-Chelating Agent for Oxidative St

  2026-05-13

  Deferoxamine mesylate is a validated iron-chelating agent with high affinity for free iron, widely utilized to inhibit iron-mediated oxidative stress and as a hypoxia mimetic in cell research. Its molecular specificity and evidence-backed applications make it a gold standard for studies in cancer biology, HIF-1α stabilization, and tissue protection.

• Resazurin Sodium Salt: Precision Viability Readouts in Metab

  2026-05-13

  Explore how Resazurin sodium salt enables precise, fluorogenic oxidation-reduction assays while illuminating the metabolic underpinnings of cell proliferation and viability. This article uniquely bridges advanced cell biology, recent fibrosis research, and practical assay optimization.

• SHC-1 Inhibition Elevates CFTR Surface Levels in Epithelia

  2026-05-12

  This study clarifies the conserved role of SHC-1, via the MAPK pathway, in mediating CFTR internalization across various epithelial cell models. By evaluating pharmacological inhibition of SHC-1, the authors reveal cell-type-specific effects on increasing plasma membrane CFTR abundance, refining mechanistic understanding for cystic fibrosis and related disease research.

• Dacarbazine: Precision DNA Damage and Translational Innovati

  2026-05-12

  This thought-leadership article unpacks the mechanistic power and translational potential of Dacarbazine as an antineoplastic chemotherapy drug. Bridging molecular DNA alkylation to clinical and experimental strategy, we deliver actionable guidance for researchers navigating malignant melanoma, Hodgkin lymphoma, and sarcoma models. We benchmark APExBIO’s Dacarbazine for robust research, compare evolving workflows, and offer future-facing insights, setting a new bar for translational oncology discourse.

• MK-1775 (Wee1 kinase inhibitor): Mechanism, Evidence & Best

  2026-05-11

  MK-1775 is a potent, selective Wee1 kinase inhibitor that abrogates the G2 DNA damage checkpoint. This agent sensitizes p53-deficient tumor cells to DNA-damaging therapies by disrupting cell cycle regulation. Quantitative benchmarks and workflow parameters support its robust application in translational cancer research.

• RNA Pol II Inhibition Triggers Apoptosis via Active Signalin

  2026-05-11

  Harper et al. (2025) reveal that cell death following RNA Pol II inhibition is mediated by an active apoptotic signaling pathway, independent of transcriptional loss. This finding reframes the mechanistic understanding of regulated cell death and suggests new approaches for apoptosis assays and cancer research.

• U0126: Selective MEK1/2 Inhibitor for MAPK/ERK Pathway Resea

  2026-05-10

  U0126 is a potent, non-ATP-competitive MEK1/2 inhibitor essential for dissecting MAPK/ERK pathway signaling. Its well-characterized selectivity and robust inhibition of ERK1/2 phosphorylation make it a gold standard for studies in cancer biology, neurobiology, and autophagy. APExBIO’s BA2003 U0126 product is widely used for reproducible and targeted research applications.

• Steroid-Induced Lysis of Protoplasts: Mechanisms and Modulat

  2026-05-09

  Smith and Shay (1965) systematically dissected the lytic action of synthetic steroids on bacterial protoplasts, revealing that membrane interactions—rather than cell wall barriers—govern antimicrobial susceptibility. Their findings inform the mechanistic understanding of polyene antifungal antibiotics, with implications for antifungal research and experimental model design.

• Dlin-MC3-DMA: Ionizable Cationic Liposome for Advanced RNA D

  2026-05-09

  Dlin-MC3-DMA stands at the forefront of RNA delivery as a potent ionizable cationic liposome, driving breakthroughs in hepatic gene silencing and targeted mRNA immunomodulation. This article translates cutting-edge research into actionable laboratory protocols, troubleshooting tips, and strategic workflow enhancements for next-generation LNP-based therapeutics.

• Torin2 mTOR Inhibitor: Applied Workflows for Cancer Research

  2026-05-08

  Torin2 sets a new benchmark as a highly selective mTOR inhibitor, enabling robust dissection of signaling pathways and cell viability in cancer research. This article offers hands-on workflow enhancements, troubleshooting strategies, and actionable protocol guidance for maximizing Torin2's impact in apoptosis assays and medullary thyroid carcinoma models.

• Local Angiotensin II Mediates Radioresistance in Nasopharyng

  2026-05-07

  This study reveals that local angiotensin II (Ang II) suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma (NPC) via the HIF-1α-HILPDA axis. The findings provide mechanistic insight into how the tumor microenvironment influences radiotherapy outcomes and suggest combined targeting of Ang II signaling and ferroptosis induction as a strategy to enhance NPC radiosensitivity.

461 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page